3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Thoracic
3
Dermatologic
3
Gynecologic
2
Genitourinary
2
CNS
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Leukemia, Lymphocytic, Chronic, B-Cell
140
Lymphoma
116
Lymphoma, Non-Hodgkin
112
Leukemia, Myeloid, Acute
95
Leukemia
92
Myelodysplastic Syndromes
90
Hodgkin Disease
68
Lymphoma, B-Cell
61
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
53
Multiple Myeloma
52
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Recurrence
43
Burkitt Lymphoma
41
Hematologic Neoplasms
36
Myeloproliferative Disorders
31
Lymphoma, B-Cell, Marginal Zone
30
Neoplasms, Plasma Cell
20
Primary Myelofibrosis
19
Leukemia, Biphenotypic, Acute
18
Anemia, Refractory, with Excess of Blasts
18
Lymphoma, T-Cell
17
Leukemia, Myelomonocytic, Chronic
15
Graft vs Host Disease
15
Anemia, Aplastic
15
Leukemia, Prolymphocytic
14
Neoplasms
12
Leukemia, B-Cell
12
Interventions
pembrolizumab
3
Sirolimus
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
spartalizumab
1
ixabepilone
1
fludarabine
1
etoposide phosphate
1
durvalumab
1
atezolizumab
1
advexin
1
Topotecan
1
Tissue Banks
1
Thiotepa
1
Radiotherapy
1
Quality of Life
1
Psychology, Positive
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Methods
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Immunotherapy
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
fludarabine
×
Lymphoid
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled